133170-58-8

Basic information

• Product Name: H-D-VAL-NH2 HCL
• Synonyms: D-Valinemide Hydrochloride;D-Valine amide hydrochloride≥ 98% (assay);H-D-VAL-NH2 HCL;D-VALINE AMIDE HYDROCHLORIDE;D-VALINAMIDE HCL;D-ValNH2.HCl;D-ValinaMide hydrochloride;(R)-2-AMino-3-MethylbutanaMide hydrochloride
• CAS NO: 133170-58-8
• Molecular Formula: C₅H₁₂N₂O*ClH
• Molecular Weight: 152.62
• Mol File: 133170-58-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Store at 0°C
• Solubility: DMSO (Slightly), Methanol (Slightly), Water (Sparingly)
• Stability: Hygroscopic
• BRN: 5759926
• CAS DataBase Reference: H-D-VAL-NH2 HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-VAL-NH2 HCL(133170-58-8)
• EPA Substance Registry System: H-D-VAL-NH2 HCL(133170-58-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 133170-58-8(Hazardous Substances Data)

Usage

Description

H-D-VAL-NH2 HCL, also known as D-Valinamide hydrochloride, is a crystalline compound with unique chemical properties. It serves as a valuable reactant in the preparation of various compounds and complexes, including lanthanide(III) complexes and carbamate analogs of fumagillin.

Uses

Used in Pharmaceutical Industry:
H-D-VAL-NH2 HCL is used as a reactant for the synthesis of pharmaceutical compounds, specifically for the preparation of lanthanide(III) complexes and carbamate analogs of fumagillin. These complexes and analogs have potential applications in the development of new drugs and therapies.
Used in Chemical Research:
H-D-VAL-NH2 HCL is used as a reactant in chemical research for the development of novel compounds and complexes. Its crystalline nature and unique chemical properties make it a valuable component in the synthesis of various substances with potential applications in different industries.
Used in Material Science:
H-D-VAL-NH2 HCL can be used as a building block in the development of new materials with specific properties. Its ability to form complexes with lanthanide(III) ions and other compounds can contribute to the creation of advanced materials for various applications, such as in electronics, optics, or sensors.

Upstream product

• 4540-60-7 L-valinamide 
• 155385-84-5 (-)-1-<(1-cyano-2-methylpropyl)amino>-2R-methyl-5R-(1-methylethenyl)-cyclohexane-1R,3R-dicarbonitrile 
• 155486-42-3 (1R,2R,3R,5R)-1-((S)-1-Cyano-2-methyl-propylamino)-5-isopropenyl-2-methyl-cyclohexane-1,3-dicarbonitrile 
• 105452-73-1 (S)-2-amino-3-methylbutanenitrile 
• 930779-35-4 9-isopropenyl-2-isopropyl-6-methyl-3-oxo-1,4-diaza-spiro[4.5]decane-7-carbonitrile 

Downstream Products

• 1374970-20-3 (R)-2-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-6-(1-amino-3-methyl-1-oxobutan-2-ylamino)-5-cyanonicotinamide 
• 32526-16-2 D-valine amide 
• 1151475-97-6 N-(1-amino-3-methyl-1-oxobutan-2-yl)-4-methoxybenzamide 

Relevant articles and documents

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of Formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of Formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.